Alector (ALEC) Climbs +70% Over 30 Days on Q2 Beat and Pipeline Momentum
Key Takeaways
- Alector (ALEC) shares climbed roughly 70% over the past 30 days, rising from about $1.43 to $2.43, driven by a better-than-expected quarterly report and renewed momentum in its neurodegeneration pipeline.
- The stock's second-quarter results exceeded consensus estimates, with a narrower loss per share and revenue that surpassed analyst forecasts.
- Over the last quarter, ALEC gained approximately 10%, reflecting a recovery from a multi-month decline rather than a sustained uptrend.
- The company remains deeply unprofitable, with modest collaboration revenue and a cash burn that keeps balance-sheet risk in focus.
- Consensus analyst sentiment is a "Hold," with price targets spanning a wide range that reflects binary clinical and funding risk.
Alector (ALEC) Company Overview and Market Position
Alector, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company develops immuno-neurology therapies designed to slow or counteract the progression of neurodegenerative diseases by engaging the brain's innate immune system. Its core focus is on conditions such as Alzheimer's disease, frontotemporal dementia (FTD), and Parkinson's disease.
ALEC's pipeline includes latozinemab and nivisnebart, progranulin-elevating antibodies being developed in collaboration with GSK, as well as the AL050 enzyme replacement program and a proprietary "Alector Brain Carrier" platform intended to help transport therapeutics across the blood-brain barrier. Investors follow the stock closely because its value is tied to upcoming clinical readouts, which carry significant binary risk alongside potentially large upside. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ALEC Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALEC advanced approximately 70%, climbing from a closing price near $1.43 to about $2.43. The move accelerated sharply in mid-August, with elevated trading volume and consecutive sessions of double-digit percentage gains that pushed the shares well above their 50-day simple moving average of roughly $1.69.
The quarterly picture is more measured. Over the trailing three months, the stock gained close to 10%, having traded near $2.21 earlier in the period before a summer slide took it toward the low-$1.40s. In that context, the recent 30-day surge largely represents a sharp recovery off a depressed base, with the shares still trading well below their 52-week high of $3.40 and above their 52-week low of $1.09.
What Drove ALEC Stock Price in the Last 30 Days
The primary catalyst was ALEC's second-quarter earnings report. The company reported a loss of $0.21 per share, beating the consensus estimate of a $0.23 loss, while revenue of $3.32 million exceeded analyst forecasts that had clustered near $1.4 million to $1.7 million. The stock rose roughly 23% in a single session on heavy volume following the results.
Beyond the headline beat, investors appeared to respond to a narrowing loss trajectory and management's continued emphasis on near-term clinical catalysts, including data readouts for its latozinemab program and progress on the Alector Brain Carrier platform. The move also reflected short-covering and momentum-driven buying in a low-float, low-priced name, with trading volumes running several times above their historical average during the rally. From what I see, this momentum phase deserves close monitoring.
What Drove ALEC Stock Performance Over the Last Quarter
The broader quarterly trend was shaped by a pullback followed by a sharp rebound. Earlier in the period, the shares drifted lower as persistent cash burn, declining year-over-year revenue, and analyst caution weighed on sentiment. Research coverage highlighted the combination of a fragile balance sheet, negative shareholders' equity, and ongoing net losses, which kept the stock under pressure near multi-year lows.
The subsequent recovery was driven by the earnings beat and a reset of investor expectations around the company's pipeline. Institutional ownership remains high at more than 85% of shares outstanding, while insider sales during the quarter — including transactions by the CEO and CFO — provided a counterweight to the improving near-term narrative. The net result was a modest quarterly gain that conceals considerable intra-period volatility.
ALEC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for ALEC are clinical and financial. Upcoming data readouts for latozinemab and progress on the Alector Brain Carrier platform are the central catalysts that could reshape the company's valuation in either direction. Investors should also monitor quarterly cash balances, which stood near $173 million in the most recent period, against an annual net loss that has exceeded $117 million on a trailing basis, as funding decisions and potential dilution remain key risks.
Analyst expectations are mixed, with a consensus "Hold" rating and price targets ranging widely from about $1.00 to $6.00, underscoring the binary nature of the investment. The next quarterly report, expected in early November, will provide an updated view on collaboration revenue, expense discipline, and the company's cash runway. As with all clinical-stage biotechs, trial outcomes and regulatory developments will remain the dominant drivers of share-price direction.
Using Tickeron AI Trading Bots for Strategy Exploration
In my own workflow, I sometimes review Tickeron’s AI Trading Bots to see how automated strategies perform across different market conditions. The platform surfaces a variety of bots that trade thousands of tickers, with details on their underlying approaches and historical results. It serves as one data point among several when I evaluate systematic signals alongside fundamental research, though it is not a standalone decision tool.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALEC sees MACD Histogram just turned negative
ALEC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 09, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 38 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ALEC moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 14 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 90 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ALEC broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on August 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +20.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 219 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 143 of 184 cases where ALEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.569) is normal, around the industry mean (18.959). P/E Ratio (0.000) is within average values for comparable stocks, (27.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.544). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (15.898) is also within normal values, averaging (426.575).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology
Advertisement